Perioperative FOLFIRI VS Adjuvant FOLFIRI in Resectable Advanced CRC Failed to Oxaliplatin
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Colorectal cancer (CRC) is one of the most leading causes of cancer death in China. Although
multiple treatment modalities including surgery, radiotherapy and chemotherapy have been
developed, the prognosis of advanced CRC still remains poor. While around 30% of resectable
advanced CRC could be cured. This study is designed to compare perioperative FOLFIRI versus
adjuvant FOLFIRI in resectable advanced CRC who exposed to oxaliplatin in open-label, phase
III mode.